Our results suggest that manipulating LMP2 expression using OBP-801 may have therapeutic implications for enhancing MHC class I presentation and improving the anti-tumor immune response in ccRCC. The gene discussed is PSMB9; the disease is nonpapillary renal cell carcinoma.